Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.

Autor:	Mamola JA; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA., Chen CY; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA., Currier MA; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA., Cassady K; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.; Division of Infectious Diseases, Nationwide Children's Hospital, Columbus, OH 43205, USA., Lee DA; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.; Division of Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43205, USA., Cripe TP; Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.; Division of Hematology/Oncology/Blood and Marrow Transplantation, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43205, USA.
Jazyk:	angličtina
Zdroj:	Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 May 04; Vol. 29, pp. 118-124. Date of Electronic Publication: 2023 May 04 (Print Publication: 2023).
DOI:	10.1016/j.omto.2023.04.008
Abstrakt:	The use of oncolytic viruses (OVs) and adoptive cell therapies (ACT) have independently emerged as promising approaches for cancer immunotherapy. More recently, the combination of such agents to obtain a synergistic anticancer effect has gained attention, particularly in solid tumors, where immune-suppressive barriers of the microenvironment remain a challenge for desirable therapeutic efficacy. While adoptive cell monotherapies may be restricted by an immunologically cold or suppressive tumor microenvironment (TME), OVs can serve to prime the TME by eliciting a wave of cancer-specific immunogenic cell death and inducing enhanced antitumor immunity. While OV/ACT synergy is an attractive approach, immune-suppressive barriers remain, and methods should be considered to optimize approaches for such combination therapy. In this review, we summarize current approaches that aim to overcome these barriers to enable optimal synergistic antitumor effects. Competing Interests: D.A.L. is an inventor on patents in cellular therapy and has licensed related technology to Sanofi. The other authors are inventors on patents or pending patents regarding oncolytic virotherapy. T.P.C. has licensed one such OV technology to Vironexis Biotherapeutics, Inc. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu